NASDAQ$WHWK
Whitehawk Therapeutics Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Aadi Bioscience reported revenue growth driven by FYARRO sales and strengthened its balance sheet through a PIPE financing.
Aadi Bioscience announced financial results for the third quarter of 2022, featuring a 24% revenue increase in FYARRO sales compared to the second quarter and the completion of a $72.5 million PIPE financing, extending the company's cash runway into 2025. The company's PRECISION 1 trial is on track, with preliminary data expected in the first half of 2023.
- Closed $72.5M PIPE financing, extending cash runway into 2025.
- PRECISION 1 trial is on track, with preliminary data expected in the first half of 2023.
- FYARRO net product sales grew by 24% over the second quarter of 2022.
- Signed clinical collaboration agreement with Mirati Therapeutics to evaluate combination therapy.
Headline financials
Revenue & EPS history
Aadi Bioscience · Revenue · Quarterly
$4.25M
Revenue by segment
Aadi Bioscience · $5.96M total across 1 segment · Q3 2023
- Product Sales, Net$5.96M—100.0%
Forward guidance
Aadi Bioscience expects to continue advancing the PRECISION 1 trial and growing FYARRO commercial efforts, and to fund research and development of additional clinical opportunities with FYARRO.
Tailwinds
- Advancement of the PRECISION 1 registrational-directed trial.
- Preliminary data from PRECISION 1 expected in the first half of 2023.
- Growing FYARRO net product sales.
- Clinical collaboration with Mirati Therapeutics.
- Extended cash runway into 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+1.8%
Avg return
Earnings day
+2.9%
Avg return
5 days after
+4.1%
Avg return
30 days after
37%
11 / 30 earnings
Positive
+69.8%
Q1 2021
Best reaction
-18.7%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.3% | -5.5% | -0.7% | |
| Q3 2025 | -0.4% | -3.5% | +10.2% | |
| Q1 2025 | +4.9% | -4.0% | -9.5% | |
| Q4 2024 | -1.5% | +1.2% | +14.7% | |
| Q3 2024 | +5.5% | +5.5% | +21.6% | |
| Q2 2024 | -3.6% | -1.4% | +30.7% | |
| Q1 2024 | -10.9% | -11.4% | -17.5% | |
| Q4 2023 | +5.7% | +9.3% | +1.0% | |
| Q3 2023 | -6.6% | -5.4% | +2.9% | |
| Q2 2023 | -1.0% | +1.7% | -12.2% | |
| Q1 2023 | -18.7% | -17.2% | -4.7% | |
| Q4 2022 | -1.8% | -0.1% | +10.3% | |
| Q3 2022 | +5.1% | +1.2% | +1.7% | |
| Q2 2022 | -6.2% | -0.9% | -11.0% | |
| Q1 2022 | +21.2% | +30.1% | +21.5% | |
| Q4 2021 | +5.4% | +2.3% | -8.2% | |
| Q3 2021 | -16.6% | -8.9% | -13.4% | |
| Q2 2021 | +3.0% | +2.0% | -7.9% | |
| Q1 2021 | +69.8% | +74.1% | +69.0% | |
| Q4 2020 | +1.9% | +2.5% | -15.1% | |
| Q3 2020 | -2.2% | +21.7% | +60.9% | |
| Q2 2020 | +17.3% | +6.4% | -22.4% | |
| Q1 2020 | -0.2% | -1.3% | +82.3% | |
| Q4 2019 | -5.8% | -17.7% | -6.2% | |
| Q3 2019 | -2.6% | -3.6% | +0.9% | |
| Q2 2019 | -1.9% | -1.9% | +0.9% | |
| Q1 2019 | -0.9% | -1.9% | -5.7% | |
| Q4 2018 | +4.2% | +22.4% | -65.0% | |
| Q3 2018 | -1.4% | -11.7% | -2.3% | |
| Q2 2018 | -1.7% | +3.9% | -3.8% | |
| Q4 2011 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro